|
1
|
Peitersen E: Bell’s palsy: the spontaneous
course of 2,500 peripheral facial nerve palsies of different
etiologies. Acta Otolaryngol Suppl. 4–30. 2002. View Article : Google Scholar
|
|
2
|
Greco A, Gallo A, Fusconi M, Marinelli C,
Macri GF and de Vincentiis M: Bell’s palsy and autoimmunity.
Autoimmun Rev. 12:323–328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Murakami S, Mizobuchi M, Nakashiro Y, Doi
T, Hato N and Yanagihara N: Bell palsy and herpes simplex virus:
identification of viral DNA in endoneurial fluid and muscle. Ann
Intern Med. 124:27–30. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lorber B: Are all diseases infectious? Ann
Intern Med. 125:844–851. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Peitersen E: Natural history of Bell’s
palsy. Acta Otolaryngol Suppl. 492:122–124. 1992. View Article : Google Scholar
|
|
6
|
Salinas RA, Alvarez G, Daly F and Ferreira
J: Corticosteroids for Bell’s palsy (idiopathic facial paralysis).
Cochrane Database Syst Rev. CD0019422010.
|
|
7
|
Lockhart P, Daly F, Pitkethly M, Comerford
N and Sullivan F: Antiviral treatment for Bell’s palsy (idiopathic
facial paralysis). Cochrane Database Syst Rev. CD0018692009.
|
|
8
|
Baugh RF, Basura GJ, Ishii LE, et al:
Clinical practice guideline: Bell’s palsy. Otolaryngol Head Neck
Surg. 149(3 Suppl): S1–S27. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ebendal T: Function and evolution in the
NGF family and its receptors. J Neurosci Res. 32:461–470. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chao MV, Rajagopal R and Lee FS:
Neurotrophin signalling in health and disease. Clin Sci (Lond).
110:167–173. 2006. View Article : Google Scholar
|
|
11
|
Deppmann CD, Mihalas S, Sharma N, Lonze
BE, Niebur E and Ginty DD: A model for neuronal competition during
development. Science. 320:369–373. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Apfel SC: Neurotrophic factor therapy -
prospects and problems. Clin Chem Lab Med. 39:351–355. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Egger M, Smith GD and Altman DG:
Systematic Reviews in Health Care: Meta-Analysis in Context. Second
edition. John Wiley & Sons, Inc; Hoboken, NJ: 2008
|
|
14
|
Sullivan FM, Swan IR, Donnan PT, et al:
Early treatment with prednisolone or acyclovir in Bell’s palsy. N
Engl J Med. 357:1598–1607. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yeo SG, Lee YC, Park DC and Cha CI:
Acyclovir plus steroid vs steroid alone in the treatment of Bell’s
palsy. Am J Otolaryngol. 29:163–166. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De Diego JI, Prim MP, De Sarriá MJ, Madero
R and Gavilán J: Idiopathic facial paralysis: a randomized,
prospective, and controlled study using single-dose prednisone
versus acyclovir three times daily. Laryngoscope. 108:573–575.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suai Z, Suqin L and Xuhua C: The clinical
efficacy of the treatment of Bell’s palsy by nerve growth factor in
45 patients. Lin Chuang Shen Jing Bing Za Zhi. 19:3922006.(In
Chinese).
|
|
18
|
Xiaomei T and Ye W: Outcome of treatment
with nerve growth fator in patients with Bell’s palsy. Lin Chuang
Yi Xue. 28:23–24. 2008.(In Chinese).
|
|
19
|
Guofen Z: Outcome of treatment with nerve
growth factor in 30 patients with Bell’s palsy. Lin Chuang He Li
Yong Yao. 3:422010.(In Chinese).
|
|
20
|
Mo J, Huang Y and Zhou W: The efficacy of
mouse nerve growth factor for injection in idiopathic facial
paralysis. Zhong Guo Yi Yao Zhi Nan. 20:32–33. 2011.(In
Chinese).
|
|
21
|
Liu XD: The efficacy of mouse nerve growth
factor for idiopathic facial paralysis in 58 patients. Zhong Guo
Zhong Xi Yi Jie He Er Bi Yan Hou Ke Za Zhi. 20:462–463. 2012.(In
Chinese).
|
|
22
|
Wang Z, Ma MJ and Han Q: Analysis the
efficacy of nerve growth factor in the treatment of facial
paralysis. Shen Jing Sun Shang Yu Gong Neng Chong Jian. 7:286–288.
2012.(In Chinese).
|
|
23
|
Li GS, Wu SG, Liu XF, Li P and Long ZZ:
Clinical efficacy analysis of the nerve growth factor in the
treatment of facial neuritis. Hei Long Jiang Yi Xue. 37:927–928.
2013.(In Chinese).
|
|
24
|
Jianwei T and Chuan D: The observation of
nerve growth factor for idiopathic facial paralysis. Jian Kang Da
Shi Ye :Yi Xue Ban. 21:46–47. 2013.(In Chinese).
|
|
25
|
Schulz KF, Chalmers I, Hayes RJ and Altman
DG: Empirical evidence of bias. Dimensions of methodological
quality associated with estimates of treatment effects in
controlled trials. JAMA. 273:408–412. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ernst E and Lee MS: A trial design that
generates only ‘positive’ results. J Postgrad Med. 54:214–216.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Levi-Montalcini R: The nerve growth factor
35 years later. Science. 237:1154–1162. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cohen S, Levi-Montalcini R and Hamburger
V: A nerve growth-stimulating factor isolated from sarcomas 37 and
180. Proc Natl Acad Sci USA. 40:1014–1018. 1954. View Article : Google Scholar
|
|
29
|
Shao H, Shu H, Wang C, Yuan W and Li Y:
Expression of nerve growth factor and its receptor in distracted
tibial nerve after limb lengthening. Anat Rec (Hoboken).
296:333–339. 2013. View
Article : Google Scholar
|
|
30
|
Yildiz M, Karlidag T, Yalcin S, et al:
Efficacy of glial growth factor and nerve growth factor on the
recovery of traumatic facial paralysis. Eur Arch Otorhinolaryngol.
268:1127–1133. 2011. View Article : Google Scholar : PubMed/NCBI
|
